MIN-102

Phase 2Small molecule

MMinoryx Therapeutics, S.L.

MIN-102 is one of 32 small molecule programs targeting X-linked adrenoleukodystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

X-Linked AdrenoleukodystrophyActive, not recruiting

AtaxiaActive, not recruiting

X-Linked AdrenoleukodystrophyPhase 2

Active, not recruiting

AtaxiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Ataxia

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Approved

1 2

Bayer Aspirin

Bayer

Phase 3

1 3

Plavix

Sanofi

Phase 3

1 4

Actos

Takeda

Phase 3

1 5

Diamox

Teva

Phase 3

1 6

Chantix

PPrism Pharmaceuticals

Phase 3

1 7

Skyclarys

Biogen

Phase 2

4 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2

1 9

Ferriprox

Chiesi Farmaceutici S.p.A.

Phase 2

2 10

Decadron

AAspen Global Incorporated

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

Completed·MMinoryx Therapeutics, S.L.·Phase 2/3·NCT03231878·105 enrolled

Ataxia1 trial

A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

Completed·MMinoryx Therapeutics, S.L.·Phase 2·NCT03917225·39 enrolled

X-linked adrenoleukodystrophy1 trial

A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

Unknown status·MMinoryx Therapeutics, S.L.·Phase 2·NCT04528706·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MIN-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MIN-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MIN-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minoryx Therapeutics, S.L. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMinoryx Therapeutics, S.L.

MIN-102

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

Ataxia1 trial

X-linked adrenoleukodystrophy1 trial

References

Drug Info

Quick Facts

Related News